Sonic's Covid Testing Volumes Set for Shallower Decline -- Market Talk
Sonic's Covid Testing Volumes Set for Shallower Decline -- Market Talk
2256 GMT - Morgans lifts its forecast for Sonic Healthcare's FY22-FY24 underlying profit by around 17%, as it now sees a shallower decline in demand for Covid-19 tests. The investment bank now expects PCR testing volumes to fall to 20M in FY22, from 30M in FY21. Previously it had foreseen a fall to 18M tests. Morgans also projects smaller declines in FY23 and FY24. "We forecast Covid testing represents between 10-23% of operating income through FY 2024," says Morgans, which rates Sonic at add. (david.winning@wsj.com; @dwinningWSJ)
2256GMT-摩根將Sonic Healthcare的22-24財年基本利潤預期上調約17%，因為該公司現在認為對新冠肺炎測試的需求降幅較小。這家投行現在預計，22財年PCR檢測量將從21財年的3000萬降至2000萬。此前，它曾預計測試次數將降至1800萬次。摩根還預計23財年和24財年的降幅較小。摩根表示：“我們預測，到2024年，Covid測試將佔到營業收入的10%-23%。”摩根對Sonic的評級為ADD。(david.win@wsj.com；@dwinningWSJ)
譯文內容由第三人軟體翻譯。